Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- California Black Health Network (CBHN)California Black Health Network Celebrates Four Decades of Advancing Black Health and Health Equity with Launch of New Impact ReportThe Impact Report launch honors the change-makers behind CBHN's impact and highlights the organization's continued commitment to creating healthier, more equitable communities across California — The California Black Health Network (CBHN)...
- Ping An Good Doctor Announces 2026 Interim ResultsCompanies: Ping An InsuranceCorporate Health Management Business Grows Steadily; AI Healthcare Empowerment Drives Continued Profitability Improvement — Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its...
- Antengene Corporation LimitedAntengene Presents Key R&D Highlights at the Evercore 2nd China Biotech SummitAntengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- Kessler Topaz Meltzer & Check, LLPKessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the FirmKessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who...
- Compassionate Care Meets Surgical Mastery: The Dr. Zainulabedin Hamdulay ApproachDr. Zainulabedin Hamdulay, an experienced cardiac surgeon known for expertise in cardiovascular and thoracic surgery, modern techniques, and patient-focused care.
- Curavit Clinical ResearchCuravit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science SponsorsCombined operations deliver unified U.S. and European trial delivery, faster recruitment, and expanded evidence-generation capabilities across pharma, biotech, medtech, diagnostics, and digital health. BOSTON, Aug. 18, 2026 -- Curavit Clinical Research, an innovative clinical...
- HelloNationIn HelloNation Routine Dental Checkup Explained Featuring Family Dental Expert Dr. Lalitha Kothuri, DDSThe article outlines what patients can expect during routine visits and how preventive dental care supports long-term oral health. — The article explains that a routine dental checkup involves much more than cleaning teeth. It describes how...
- Noveris Health Sciences Inc.Noveris Health Sciences Receives USPTO Notice of Allowance, and Signs Work Order with APINoveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) ("Noveris" or the "Company") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's U.S. Patent Application No. 18/443,025, titled "Aza-Substituted Psilocin Analogs and Methods of Synthesizing the Same."The Notice of Allowance confirms that all six claims in the application have...
- IM Cannabis Corp.IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price ComplianceIM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, announces that the board of directors of the Company (the "Board") has approved a consolidation of its...
- Ottawa’s Inaction Lets Smith Destroy Health CareEDMONTON, AB, August 18, 2026--CUPE Alberta President Raj Uppal is calling out the Liberal government in Ottawa for its inaction while the UCP dramatically expands private, patient paid health care in the province.
- Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD TreatmentFollows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on August 17, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 11,000 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).